Indications for: VIZAMYL
For PET imaging of the brain to estimate β-amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. As an adjunct to other diagnostic evaluations.
Limitations of Use:
A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and efficacy not established for predicting development of dementia or other neurologic conditions, or for monitoring responses to therapies.
See full labeling. Give 185MBq (5mCi), max 20μg mass dose, as a single IV bolus in a total volume of ≤10mL within 40 seconds. Follow injection with 5–15mL IV flush of 0.9% sterile NaCl. Starting 60–120mins after IV inj, acquire a 10–20min PET image. The radiation absorbed dose from 185MBq (5mCi) dose is 5.92mSv.
Allergy to polysorbate 80.
Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk of image misinterpretation and other errors. Perform image interpretation independently of patient's clinical information. Pregnancy. Nursing mothers: not recommended, or temporarily interrupt for 24hrs after Vizamyl exposure.
Radioactive diagnostic agent.
Flushing, headache, increased blood pressure, nausea, dizziness; hypersensitivity reactions.
Generic Drug Availability:
Multi-dose vials (30mL)—1